Research Solutions Reports Earnings Results, Falls Short of Estimates

Research Solutions (NASDAQ:RSSS) announced its quarterly earnings on Thursday, revealing that the company reported an earnings per share (EPS) of ($0.07) for the quarter. This figure was below the analysts' consensus estimate of $0.02, falling short by $0.09. According to Zacks, this underperformance highlights the challenges the company is currently facing in the market.

In terms of profitability metrics, Research Solutions reported a negative net margin of 4.57%, indicating expenses exceeded revenues for the period. Conversely, the company demonstrated a positive return on equity, which stood at 8.43%, reflecting its capability to generate profit from shareholders' equity despite the losses per share.

Stock Performance of Research Solutions

On the day of the earnings release, Research Solutions' stock saw an uptick of 2.1%, increasing by $0.08 to a trading price of $3.91. The volume of shares traded that day was 78,831 which is considerably lower than the average volume of 134,970 shares. Furthermore, the company holds a market capitalization of approximately $128.33 million, with a price-to-earnings (P/E) ratio of -48.88 and a P/E/G ratio of 5.03. The stock has maintained a 50-day moving average price of $3.91 and a 200-day moving average price of $3.19, while its fifty-two week performance indicates a low of $2.38 and a high of $4.24.

About Research Solutions

Research Solutions, Inc. operates through its subsidiaries and specializes in providing a cloud-based software-as-a-service platform for research. They cater to a diverse clientele including corporate, academic, government, and individual researchers across the United States, Europe, and beyond. Their primary product, the Discover platform, aids in the search and discovery of a wide range of scientific, technical, and medical (STM) articles. This includes basic search solutions as well as advanced search tools such as Resolute.ai and scite.ai, which facilitate the identification and exploration of relevant research by integrating insights from various datasets tied to STM content, including clinical trials, patents, and life sciences regulatory information.

Earnings, Stock, Company